<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987802</url>
  </required_header>
  <id_info>
    <org_study_id>NN1218-4489</org_study_id>
    <secondary_id>U1111-1222-9492</secondary_id>
    <nct_id>NCT03987802</nct_id>
  </id_info>
  <brief_title>An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice</brief_title>
  <official_title>An Indian Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Fiasp® to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with&#xD;
      diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is&#xD;
      prescribed to the participants by their doctors. Participants will administer Fiasp® as&#xD;
      prescribed by their doctors. The study will last for about 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Number of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions (ADRs)</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Drug Reactions (SADRs)</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported severe hypoglycaemia</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Episodes/person-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Blood Glucose (BG) confirmed (below 56 mg/dl) hypoglycaemia</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Episodes/person-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Severe or BG confirmed (below 56 mg/dl) hypoglycaemia</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Episodes/person-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>From start of treatment (Week 0) to End of Study Visit (Week 26)</time_frame>
    <description>Percent point (%)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Fiasp®</arm_group_label>
    <description>Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faster-acting insulin aspart</intervention_name>
    <description>Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.</description>
    <arm_group_label>Fiasp®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice&#xD;
        in India.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any study-related activities. Study-related&#xD;
             activities are any procedures that are carried out as part of the study, including&#xD;
             activities to determine suitability for the study.&#xD;
&#xD;
          -  Male or female, age equal to or above 18 years at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Patients diagnosed with diabetes mellitus.&#xD;
&#xD;
          -  Patients scheduled to start treatment with Fiasp® based on the clinical judgement of&#xD;
             their treating physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to study product(s) or related products.&#xD;
&#xD;
          -  Patients on or likely to use insulin pump therapy during the study period&#xD;
&#xD;
          -  Previous participation in this study. Participation is defined as having given signed&#xD;
             informed consent.&#xD;
&#xD;
          -  Mental incapacity, unwillingness or language barriers hindering adequate understanding&#xD;
             or cooperation.&#xD;
&#xD;
          -  Participation in any clinical study of an approved or non-approved investigational&#xD;
             medicinal product within 1 month before treatment start.&#xD;
&#xD;
          -  Any disorder which in the opinion of the treating physician may jeopardise the&#xD;
             patient's safety or compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

